| A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations (NCT05420779) | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | 2022-06-30 |
| The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study (NCT05463276) | Sindh Institute of Urology and Transplantation | 2022-02-28 |
| Sitravatinib in Metastatic Breast Cancer (NCT04123704) | Xiang Zhang | 2021-09-22 |
| ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL (NCT04603183) | MedSIR | 2021-06-02 |
| Radiotherapy for Extracranial Oligometastatic Breast Cancer (NCT04646564) | Chinese Academy of Medical Sciences | 2021-04-06 |
| Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (NCT04659603) | Sanofi | 2021-03-29 |
| Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (NCT05033769) | Institut fuer Frauengesundheit | 2021-03-11 |
| SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (NCT04150042) | General Oncology, Inc. | 2021-01-13 |
| Real World Study of Bone Metastases in Patients with Advanced Breast Cancer (NCT06873997) | Zhejiang Cancer Hospital | 2021-01-01 |
| Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (NCT04483505) | Fundacion CRIS de Investigación para Vencer el Cáncer | 2020-11-25 |
| DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer (NCT04509596) | Dizal Pharmaceuticals | 2020-09-21 |
| A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients (NCT04556292) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2020-08-12 |
| Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) (NCT04240106) | MedSIR | 2020-06-15 |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study (NCT04215146) | Oncolytics Biotech | 2020-06-10 |
| Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases (NCT04167605) | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 2020-01-13 |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC (NCT04262804) | Zai Lab (Shanghai) Co., Ltd. | 2020-01-13 |
| A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer (NCT04197999) | GlycoMimetics Incorporated | 2019-11-21 |
| NR in Chemo-induced Peripheral Neuropathy (NCT03642990) | Donna Hammond, PhD | 2019-11-08 |
| Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer (NCT05609903) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2019-11-01 |
| Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (NCT04059484) | Sanofi | 2019-10-22 |
| Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation (NCT04368442) | Samsung Medical Center | 2019-10-17 |
| The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease (NCT04122469) | University Health Network, Toronto | 2019-09-11 |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer (NCT03742245) | The Methodist Hospital Research Institute | 2019-06-11 |
| Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. (NCT05301530) | Nanogen Pharmaceutical Biotechnology Joint Stock Company | 2019-05-27 |
| Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings. (NCT05155566) | Pfizer | 2019-05-15 |
| Personalised Disease Monitoring in Metastatic Breast Cancer (NCT04597580) | The Christie NHS Foundation Trust | 2019-05-08 |
| Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer (NCT04350021) | Vastra Gotaland Region | 2019-03-01 |
| Screening For BCRL In Targeted Therapy For Breast Cancer (NCT05142800) | Massachusetts General Hospital | 2018-12-13 |
| Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer (NCT03638765) | Northwest Biotherapeutics | 2018-11-01 |
| Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (NCT03709082) | University of Kansas Medical Center | 2018-10-15 |
| Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System (NCT03427450) | Angle plc | 2018-03-29 |
| Combination Study of SV-BR-1-GM With Retifanlimab (NCT03328026) | BriaCell Therapeutics Corporation | 2018-03-16 |
| Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (NCT03555877) | GBG Forschungs GmbH | 2018-03-15 |
| Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients (NCT05301010) | Nanogen Pharmaceutical Biotechnology Joint Stock Company | 2018-02-02 |
| MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. (NCT03321981) | Merus B.V. | 2018-01-15 |
| HR+/HER2- Advanced Breast Cancer and Endocrine Resistance (NCT03322215) | Theodoros Foukakis | 2017-10-24 |
| E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research (NCT03132506) | University Hospital Tuebingen | 2017-06-01 |
| Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients (NCT03328884) | MedSIR | 2017-05-02 |
| Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer (NCT03086785) | Hebei Medical University Fourth Hospital | 2016-11-24 |
| Investigation of Cancer Cell Extravasation Through mRNA Analysis of Organ-specific Endothelial Cells and Microfluidics (NCT04047459) | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 2016-06-06 |
| GISEL:Registry of Breast Cancer Patients Treated With ECT (NCT06683404) | Istituto Oncologico Veneto IRCCS | 2016-04-22 |
| Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer (NCT02664103) | Sanofi | 2016-01-23 |
| Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer (NCT03002532) | Affiliated Hospital to Academy of Military Medical Sciences | 2015-08-01 |
| Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (NCT02511639) | Istituto Oncologico Veneto IRCCS | 2014-07-30 |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (NCT02000622) | AstraZeneca | 2014-03-27 |
| A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer (NCT01876251) | Pfizer | 2013-11-04 |
| Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer (NCT01067989) | HaEmek Medical Center, Israel | 2010-03-01 |
| Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer (NCT01045304) | Sanofi | 2010-02-01 |
| Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC (NCT00532714) | National Cancer Center, Korea | 2006-08-01 |
| Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer (NCT00288249) | Bayer | 2005-12-01 |
| Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients (NCT00044525) | Bayer | 2002-04-01 |
| Study for Using Radiosurgery on Limited Metastases of Breast Cancer (NCT00167414) | University of Rochester | 2000-12-01 |